INTS vs OKTA · $7.7M cap vs P/E 84, rev $2.61B
Intensity Therapeutics, Inc. Common stock (INTS) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
INTS does not have a complete income-statement cache yet.
Latest reported OKTA revenue for 2025-01-31 was $2.61B. Net income was $28.0M. Revenue was up 15.3% from 2024-01-31 to 2025-01-31. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
INTS currently screens at market cap $7.7M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the INTS and OKTA stock pages for the full models.
Not investment advice.